This article is more than 5 years old. Information may no longer be current.

AcrySof IOL shows good long-term biocompatibility in children

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PARIS — In a 6-year follow-up study on implantation of the AcrySof IOL in children under 5 years old, the IOL showed good biocompatibility in surgical correction of aphakia for congenital and/or developmental cataract.

Pedro Faria, MD, reported the results of the long-term study here at the European Society of Cataract and Refractive Surgeons meeting.

Dr. Faria followed 57 eyes that were implanted with the AcrySof over the course of 6 years. There were six cases of cellular deposits on the surface of the IOL, two cases of secondary pupillary membranes that were successfully treated with steroids and five cases of opacification of the visual axis. Secondary surgical procedures were needed in five cases of visual axis opacification.